Valeritas’ V-Go Wearable Insulin Delivery Device Reduces A1C, Insulin Requirements

Valeritas Holdings Inc., a developer and commercializer of diabetes treatment technologies, announced positive findings from a analysis conducted combining its V-Go Wearable Basal plus Bolus Insulin Delivery Device with a weekly physician-driven, simplified prandial-focused insulin titration algorithm. Achievement of glycemic targets occurred in two-thirds of patients and patient-reported hypoglycemia was decreased by study end utilizing this therapeutic approach to insulin management. Results from this study were presented recently at the 17th Annual Diabetes Technology Meeting in Bethesda, Md.
 
“This proof-of-concept study demonstrates that a simplified prandial or bolus focused weekly insulin titration algorithm in patients with Type 2 diabetes (T2D) prescribed V-Go can be used effectively and safely, leading to significantly improved glycemic control while also lowering the mean total daily insulin dose of insulin,” said John Timberlake, president and CEO of Valeritas. “The results are very promising and support the importance of addressing post prandial glucose to achieve glycemic targets.”
 
MOTIV4CONTROL— flagship product, V-Go Wearable Insulin Delivery device, is a wearable, basal-bolus insulin delivery device for type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market specifically designed for the needs of type 2 diabetes patients. Headquartered in Bridgewater, N.J., Valeritas operates its R&D functions in Marlborough, Mass.